Bradley R. Prestidge, MD
The addition of external-beam radiotherapy (EBRT) to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease, interim data from a randomized trial showed.1,2
Follow-up will continue until the data reach a cutoff for efficacy or futility, Bradley R. Prestidge, MD, a radiation oncologist at Bon Secours Cancer Institute and DePaul Medical Center, reported at the 2016 American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston, Massachusetts.
“Among men with intermediate-risk prostate cancer, the addition of external-beam therapy to brachytherapy did not result in superior freedom from progression compared with brachytherapy alone at 5 years in this initial report,” Prestidge concluded. “Toxicity in both groups was limited, but there were fewer late effects, mostly genitourinary, noted in the brachytherapy-alone arm.”
... to read the full story